BUY Zydus Lifesciences — Ajit Mishra, 12 Aug 2026

BUYZydus Lifesciences Limited

Zydus Lifesciences share price target & all analyst calls

byAjit Mishra, ReligareHorizon: NA (inferred Swing (≤2wk))12 Aug 2026via NDTV Profit (Live)

Entry₹1,161.6Inferred

Target₹1,320

Total upside +13.64%

Stop loss₹1,130-2.72% risk

Exit₹1,13017 Aug 2026, 9:20 am

Stop-loss hit-2.72%

Follow Ajit Mishra for new calls(21% target hit, 114 closed calls)Get alerts Watch ZYDUSLIFE for new buy/sell callsGet alerts See 105 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 17 Aug 2026

11 supporting6 neutral3 opposing

Supports the BUY call (11)

Zydus Lifesciences Limited's subsidiary, Sentynl Therapeutics, has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential treatment for Alpha-1 Antitrypsin Defic

NSE · Press Release·11 Aug · 5d ago

Zydus Lifesciences' subsidiary Sentynl Therapeutics has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential treatment for Alpha-1 Antitrypsin Deficiency-Assoc

BSE · Company Update·11 Aug · 5d ago

Zydus Lifesciences Q1 Results: Stock jumps over 6%; India biz leads growth

NewsCnbc-Tv18·11 Aug · 5d ago

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·12 Aug · 5d ago

Macquarie Hikes Zydus Lifesciences' Target Ahead Of Q1 Results; Bets On New Business Buildout To Drive Growth

NewsNdtv-Profit·11 Aug · 6d ago

Neutral / worth noting (6)

From Zydus Lifesciences To Greenpanel: Check HDFC Securities' Latest Q1 Ratings, Target Prices, Outlook

NewsNdtv-Profit·12 Aug · 4d ago

Zydus Lifesciences Limited has submitted a press release regarding its unaudited financial results for the quarter ended June 30, 2026. The filing is a disclosure under SEBI regulations.

NSE · Press Release·11 Aug · 5d ago

Zydus Lifesciences Ltd has submitted a press release regarding its unaudited financial results for the quarter ended June 30, 2026, as per SEBI regulations.

BSE · Company Update·11 Aug · 5d ago

Unaudited financial results for the quarter ended on June 30, 2026

BSE · Board Meeting·11 Aug · 5d ago

Zydus Lifesciences Q1 Results Today: Time, Earnings Call, What To Watch, Share Price

NewsNdtv-Profit·11 Aug · 6d ago

Weighs against the BUY call (3)

Zydus Lifesciences shares drop 3% after Q1 earnings. Here's why Nuvama upgraded rating, hiked target

NewsEt-Markets·12 Aug · 4d ago

Zydus Lifesciences Q1 Results: Net profit down 36% at Rs 939.8 crore

NewsEt-Markets·11 Aug · 5d ago

Zydus Lifesciences received an order from the Superintendent of Stamps, Gandhinagar, demanding recovery of ₹53.47 million in deficient stamp duty and ₹55.07 million in penalties, totaling ₹108.54 mill

BSE · Company Update·29 Jul · 3w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Ajit Mishra, Religare

Every call and its outcome

BUY Zydus Lifesciences Limited — Ajit Mishra, Religare

AI Assessment

Other calls on Zydus Lifesciences

More from Ajit Mishra, Religare